Table 5.

Results (toxicity) comparison with randomized studies.

Study	Number of pts	Adjuvant therapy	Toxicity scores	Acute toxicity		Late toxicity
				GI	GU	GI	GU
Thompson et al., 2006 [5]	214	RT: 60–64 Gy (2 Gy/fraction) to prostatic fossa and periprostatic tissue	NR	NR	NR	Proctitis and/or rectal bleeding: 3.3% ∗	Urethral stricture: 17.8%; total urinary incontinence: 6.5% ∗
Wiegel et al., 2009 [3] (ARO 96-02/AUO AP 09/95)	114	RT: 60 Gy (2 Gy/fraction) to prostatic fossa and region of seminal vesicles with 1 cm margin	Acute: RTOG Late: RTOG-EORTC	NR	NR	G2: 1.4% G3: 0% †	G2: 2%; G3: 0.7%; urethral stricture: 1.4% †
Bolla et al., 2012 [4] (EORTC 22911)	502	RT: 50 Gy (2 Gy/fraction) to prostatic fossa and region of seminal vesicles and periprostatic area + 10 Gy to prostatic fossa	NR	NR	NR	G ≥ 2: 2.5% ‡	G ≥ 2: 21.3% ‡
						Late GI-GU G ≥ 1: 70.8%
						Late GI-GU G3: 5.3%
						Late GI-GU G4: 0%
						‡
Present series	123	RT: 64.8–70.2 Gy (1.8 Gy/fraction) to prostatic fossa and region of seminal vesicles with 1 cm margin ± ENI, 45 Gy ± AHT	Acute: RTOG Late: RTOG-EORTC	G3: 2.4% G4: 0.0%	G3: 3.3% G4: 0.0%	G ≥ 2: 3.7% G ≥ 3: 0.0% G ≥ 4: 0.0% §	G ≥ 2: 12.7% G ≥ 3: 5.8% G ≥ 4: 0.0% §

ENI: elective nodal irradiation; GI: gastrointestinal; GU: genitourinary; AHT: adjuvant hormonal therapy; NR: not reported; pts: patients; ∗: crude (median follow-up: 10.6 years); †: crude (median follow-up: 53.7 months); ‡: 10-year cumulative incidence; and §: 5-year actuarial cumulative incidence.